Pharmaceutical Business Review
Return to: PBR Home

News

View news from other Pharmaceutical sectors:
31-45 of 51311 results
Sirnaomics secures $25m to expand clinical programs of anti-fibrosis and anti-cancer RNAi therapeutics
Sirnaomics, a biopharmaceutical company in development of RNAi therapeutics, has closed Series C1 financing of $25m.
Drug Research > Drug Discovery & Development > News
AbbVie’s upadacitinib succeeds in phase 3 trial in rheumatoid arthritis
AbbVie said that the phase 3 SELECT-EARLY trial evaluating two doses of upadacitinib (15 mg and 30 mg) as monotherapy in the treatment of rheumatoid arthritis met the primary endpoints of ACR50a at week 12 and clinical remissionb at week 24 versus methotrexate (MTX).
Contract Research & Services > Clinical Trials > News
Pfizer to invest $600m in biotechnology and other growth companies
By PBR Staff Writer
Pfizer said that it will invest $600m in biotechnology and other emerging growth firms through its venture capital arm Pfizer Ventures for the development of life-changing therapies to patients in need.
Drug Research > Drug Discovery & Development > News
Nimbus Therapeutics raises $65m in new capital to expand discovery efforts
Nimbus Therapeutics has raised $65m in new capital to accelerate its pipeline progress and fuel its expansion into new high-value targets aimed at overlapping biological mechanisms in immunology, oncology and metabolic disease.
Drug Research > Drug Discovery & Development > News
Hookipa, Gilead to jointly develop therapeutics against HIV and Hepatitis B infections
Hookipa Biotech has granted exclusive rights to Gilead Sciences to use its TheraT and Vaxwave arenavirus vector-based immunization technologies to develop Immunotherapies for hepatitis B virus (HBV) and human immunodeficiency virus (HIV).
Drug Research > Drug Discovery & Development > News
Roche’s Hemlibra gets FDA priority review for new haemophilia A indication
By PBR Staff Writer
Roche’s Hemlibra (emicizumab) has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of haemophilia A without factor VIII inhibitors in both adults and children.
Production & Manufacturing > Process & Production > News
Mylan, Biocon secure FDA nod for first biosimilar to cancer drug Neulasta
By PBR Staff Writer
Mylan and Biocon have secured approval from the US Food and Drug Administration for Fulphila (pegfilgrastim-jmbd), a biosimilar to Amgen’s cancer drug Neulasta (pegfilgrastim).
Regulatory Affairs > News
ENYO Pharma raises €40m to pursue phase II clinical development of HBV and NASH drug
Privately held clinical stage biopharmaceutical firm ENYO Pharma has completed a €40m series B round of financing from US and European investors.
Drug Research > Drug Discovery & Development > News
Virpax licenses LipoCure’s Liposome drug delivery technology
Virpax Pharmaceuticals has signed a technology license agreement with LipoCure to develop pain management products using the latter’s liposome drug delivery technology.
Drug Research > Drug Delivery > News
AstraZeneca says Lynparza/abiraterone combo delayed disease progression in mCRPC
By PBR Staff Writer
AstraZeneca has reported that Lynparza (olaparib) in combination with abiraterone succeeded in a phase II trial by delaying disease progression in metastatic castration-resistant prostate cancer (mCRPC) patients.
Contract Research & Services > Clinical Trials > News
European Commission approves Perjeta and Herceptin combo
The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery treatment of adults with HER2-positive early breast cancer (eBC) at high risk of recurrence.
Regulatory Affairs > News
Novartis phase III trial shows Kisqali combo therapy improves PFS in HR+/HER2- advanced breast cancer
Novartis has reported positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer.
Contract Research & Services > Clinical Trials > News
Lilly and Incyte gain FDA approval for lower dose of RA drug Olumiant
The US Food and Drug Administration (FDA) has approved a lower dose of Olumiant (baricitinib), a daily once oral Janus kinase (JAK) inhibitor developed by Lilly and Incyte to treat moderately-to-severely active rheumatoid arthritis (RA).
Regulatory Affairs > News
Merck’s Keytruda shows improved ORR in phase 2 renal cell carcinoma study
By PBR Staff Writer
A phase 2 trial assessing Merck’s Keytruda (pembrolizumab) demonstrated overall response rate (ORR) of about 40% as first-line therapy in patients with advanced clear cell renal cell carcinoma (RCC).
Contract Research & Services > Clinical Trials > News
Syndax, Nektar Therapeutics announce immuno-oncology clinical trial collaboration
Syndax Pharmaceuticals and Nektar Therapeutics have entered into a non-exclusive immuno-oncology clinical trial collaboration.
Contract Research & Services > Clinical Trials > News
31-45 of 51311 results